Ho Chul Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ho Chul Kang has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
Soyeon Kim
Genomic Instability Research Center, Ajou University, School of Medicine , Suwon 16499
9 shared publicationsSeo Yun Lee
Genomic Instability Research Center, Ajou University, School of Medicine , Suwon 16499
8 shared publicationsYiseul Hwang
Department of Biomedical Sciences, Graduate School, Ajou University School of Medicine, Suwon, 16499, Republic of Korea
8 shared publications- Hyeseong Cho
Department of Biochemistry, Ajou University School of Medicine, Suwon, Korea
5 shared publications Jee Min Chung
Genomic Instability Research Center, Ajou University School of Medicine, Suwon, Gyeonggi, 16499, Republic of Korea
5 shared publicationsDongsun Park
Department of Biology Education Korea National University of Education Cheongju Chungbuk 29173 South Korea
4 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (63) , e77271
RSF1‐Dependent PAR Turnover Promotes 53BP1 Liquid Condensate Formation at DNA Damage Sites
Liquid–liquid phase separation (LLPS) is essential for proper DNA damage signaling. The sequential formation of PAR‐ and 53BP1‐based condensates must be tightly controlled in space and time, however the molecular regulators of this process remain insufficiently defined. Here, we show that RSF1 contains a substantial proportion of intrinsically disordered regions (IDRs) and participates in the sequential assembly of liquid condensates at DSB sites. RSF1 depletion severely abolishes 53BP1 optoDroplet formation without affecting FUS condensates, but causes persistent PAR chains due to defective PARG recruitment. Domain mapping reveals that the C‐terminal region of the IDR in RSF1 is sufficient to support 53BP1 condensate formation. Mechanistically, RSF1 controls the timely extinction of PAR chains by promoting the recruitment of PARG, but not PARP1, to DNA damage sites. This regulation enables the transition from PAR‐based scaffolds to 53BP1 condensates. Importantly, defects in RSF1‐mediated condensate formation correlate with impaired transcription of p53 target genes, including p21CIP1. Together, these findings establish RSF1 as a molecular coordinator that links PAR turnover to 53BP1 condensate assembly, thereby coupling the spatial and temporal regulation of LLPS with p53‐dependent transcriptional responses at DNA lesions.
- 24 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (63) , e77271
Open AccessRSF1‐Dependent PAR Turnover Promotes 53BP1 Liquid Condensate Formation at DNA Damage Sites
Liquid–liquid phase separation (LLPS) is essential for proper DNA damage signaling. The sequential formation of PAR‐ and 53BP1‐based condensates must be tightly controlled in space and time, however the molecular regulators of this process remain insufficiently defined. Here, we show that RSF1 contains a substantial proportion of intrinsically disordered regions (IDRs) and participates in the sequential assembly of liquid condensates at DSB sites. RSF1 depletion severely abolishes 53BP1 optoDroplet formation without affecting FUS condensates, but causes persistent PAR chains due to defective PARG recruitment. Domain mapping reveals that the C‐terminal region of the IDR in RSF1 is sufficient to support 53BP1 condensate formation. Mechanistically, RSF1 controls the timely extinction of PAR chains by promoting the recruitment of PARG, but not PARP1, to DNA damage sites. This regulation enables the transition from PAR‐based scaffolds to 53BP1 condensates. Importantly, defects in RSF1‐mediated condensate formation correlate with impaired transcription of p53 target genes, including p21CIP1. Together, these findings establish RSF1 as a molecular coordinator that links PAR turnover to 53BP1 condensate assembly, thereby coupling the spatial and temporal regulation of LLPS with p53‐dependent transcriptional responses at DNA lesions.
- Open Access
- 10 April 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (7)
Proteome-wide microarray-based screening of PAR-binding proteins
Poly (ADP-ribose) (PAR) plays a crucial role in intracellular signaling and scaffolding through covalent modification or non-covalent binding to target proteins. The non-covalent PAR binding proteome (PARylome) has not been extensively characterized. Here we performed a PAR-binding screen using a human protein microarray that covers most of the human proteome to characterize the non-covalent binding PARylome. A total of 356 PAR-binding proteins were identified. The PAR-binding PARylome suggests that PAR binding regulates a variety of biological processes beyond DNA damage signaling and DNA repair. Proteins that may be reprogrammed by PAR binding include signaling molecules, transcription factors, nucleic acid binding proteins, calcium binding proteins, ligases, oxidoreductases, enzymes, transferases, hydrolases, and receptors. The global database of PAR-binding proteins that we established will be a valuable tool for further in-depth analysis of the role of PARylation in a wide range of biological contexts.
- 10 April 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (7)
Open AccessProteome-wide microarray-based screening of PAR-binding proteins
Poly (ADP-ribose) (PAR) plays a crucial role in intracellular signaling and scaffolding through covalent modification or non-covalent binding to target proteins. The non-covalent PAR binding proteome (PARylome) has not been extensively characterized. Here we performed a PAR-binding screen using a human protein microarray that covers most of the human proteome to characterize the non-covalent binding PARylome. A total of 356 PAR-binding proteins were identified. The PAR-binding PARylome suggests that PAR binding regulates a variety of biological processes beyond DNA damage signaling and DNA repair. Proteins that may be reprogrammed by PAR binding include signaling molecules, transcription factors, nucleic acid binding proteins, calcium binding proteins, ligases, oxidoreductases, enzymes, transferases, hydrolases, and receptors. The global database of PAR-binding proteins that we established will be a valuable tool for further in-depth analysis of the role of PARylation in a wide range of biological contexts.
- Open Access
- 1 January 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 43, 305-318
An intra articular injectable Mitocelle recovers dysfunctional mitochondria in cellular organelle disorders
Mitochondrial dysfunction increases ROS production and is closely related to many degenerative cellular organelle diseases. The NOX4-p22phox axis is a major contributor to ROS production and its dysregulation is expected to disrupt mitochondrial function. However, the field lacks a competitive inhibitor of the NOX4-p22phox interaction. Here, we created a povidone micelle-based Prussian blue nanozyme that we named “Mitocelle” to target the NOX4-p22phox axis, and characterized its impact on the major degenerative cellular organelle disease, osteoarthritis (OA). Mitocelle is composed of FDA-approved and biocompatible materials, has a regular spherical shape, and is approximately 88 nm in diameter. Mitocelle competitively inhibits the NOX4-p22phox interaction, and its uptake by chondrocytes can protect against mitochondrial malfunction. Upon intra-articular injection to an OA mouse model, Mitocelle shows long-term stability, effective uptake into the cartilage matrix, and the ability to attenuate joint degradation. Collectively, our findings suggest that Mitocelle, which functions as a competitive inhibitor of NOX4-p22phox, may be suitable for translational research as a therapeutic for OA and cellular organelle diseases related to dysfunctional mitochondria.
- 1 January 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 43, 305-318
Open AccessAn intra articular injectable Mitocelle recovers dysfunctional mitochondria in cellular organelle disorders
Mitochondrial dysfunction increases ROS production and is closely related to many degenerative cellular organelle diseases. The NOX4-p22phox axis is a major contributor to ROS production and its dysregulation is expected to disrupt mitochondrial function. However, the field lacks a competitive inhibitor of the NOX4-p22phox interaction. Here, we created a povidone micelle-based Prussian blue nanozyme that we named “Mitocelle” to target the NOX4-p22phox axis, and characterized its impact on the major degenerative cellular organelle disease, osteoarthritis (OA). Mitocelle is composed of FDA-approved and biocompatible materials, has a regular spherical shape, and is approximately 88 nm in diameter. Mitocelle competitively inhibits the NOX4-p22phox interaction, and its uptake by chondrocytes can protect against mitochondrial malfunction. Upon intra-articular injection to an OA mouse model, Mitocelle shows long-term stability, effective uptake into the cartilage matrix, and the ability to attenuate joint degradation. Collectively, our findings suggest that Mitocelle, which functions as a competitive inhibitor of NOX4-p22phox, may be suitable for translational research as a therapeutic for OA and cellular organelle diseases related to dysfunctional mitochondria.
- Open Access
- 1 September 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (19) , 11720-11737
PARP1-TRIM44-MRN loop dictates the response to PARP inhibitors
PARP inhibitors (PARPi) show selective efficacy in tumors with homologous recombination repair (HRR)-defects but the activation mechanism of HRR pathway in PARPi-treated cells remains enigmatic. To unveil it, we searched for the mediator bridging PARP1 to ATM pathways by screening 211 human ubiquitin-related proteins. We discovered TRIM44 as a crucial mediator that recruits the MRN complex to damaged chromatin, independent of PARP1 activity. TRIM44 binds PARP1 and regulates the ubiquitination-PARylation balance of PARP1, which facilitates timely recruitment of the MRN complex for DSB repair. Upon exposure to PARPi, TRIM44 shifts its binding from PARP1 to the MRN complex via its ZnF UBP domain. Knockdown of TRIM44 in cells significantly enhances the sensitivity to olaparib and overcomes the resistance to olaparib induced by 53BP1 deficiency. These observations emphasize the central role of TRIM44 in tethering PARP1 to the ATM-mediated repair pathway. Suppression of TRIM44 may enhance PARPi effectiveness and broaden their use even to HR-proficient tumors.
- 1 September 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (19) , 11720-11737
Open AccessPARP1-TRIM44-MRN loop dictates the response to PARP inhibitors
PARP inhibitors (PARPi) show selective efficacy in tumors with homologous recombination repair (HRR)-defects but the activation mechanism of HRR pathway in PARPi-treated cells remains enigmatic. To unveil it, we searched for the mediator bridging PARP1 to ATM pathways by screening 211 human ubiquitin-related proteins. We discovered TRIM44 as a crucial mediator that recruits the MRN complex to damaged chromatin, independent of PARP1 activity. TRIM44 binds PARP1 and regulates the ubiquitination-PARylation balance of PARP1, which facilitates timely recruitment of the MRN complex for DSB repair. Upon exposure to PARPi, TRIM44 shifts its binding from PARP1 to the MRN complex via its ZnF UBP domain. Knockdown of TRIM44 in cells significantly enhances the sensitivity to olaparib and overcomes the resistance to olaparib induced by 53BP1 deficiency. These observations emphasize the central role of TRIM44 in tethering PARP1 to the ATM-mediated repair pathway. Suppression of TRIM44 may enhance PARPi effectiveness and broaden their use even to HR-proficient tumors.
- Open Access
- 7 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 8612
Anti-TCP1 Antibody Is a Potential Biomarker for Diagnosing Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease caused by autoantibodies. Serum samples from patients with SLE (n = 10) were compared with those from normal controls (NCs, n = 5) using 21K protein chip analysis to identify a biomarker for SLE, revealing 63 SLE-specific autoantibodies. The anti-chaperonin-containing t-complex polypeptide-1 (TCP1) antibody exhibited higher expression in patients with SLE than in NCs. To validate the specificity of the anti-TCP1 antibody in SLE, dot blot analysis was conducted using sera from patients with SLE (n = 100), rheumatoid arthritis (RA; n = 25), Behçet’s disease (BD; n = 28), and systemic sclerosis (SSc; n = 30) and NCs (n = 50). The results confirmed the detection of anti-TCP1 antibodies in 79 of 100 patients with SLE, with substantially elevated expression compared to both NCs and patients with other autoimmune diseases. We performed an enzyme-linked immunosorbent assay to determine the relative amounts of anti-TCP1 antibodies; markedly elevated anti-TCP1 antibody levels were detected in the sera of patients with SLE (50.1 ± 17.3 arbitrary unit (AU), n = 251) compared to those in NCs (33.9 ± 9.3 AU), RA (35 ± 8.7 AU), BD (37.5 ± 11.6 AU), and SSc (43 ± 11.9 AU). These data suggest that the anti-TCP1 antibody is a potential diagnostic biomarker for SLE.
- 7 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 8612
Open AccessAnti-TCP1 Antibody Is a Potential Biomarker for Diagnosing Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease caused by autoantibodies. Serum samples from patients with SLE (n = 10) were compared with those from normal controls (NCs, n = 5) using 21K protein chip analysis to identify a biomarker for SLE, revealing 63 SLE-specific autoantibodies. The anti-chaperonin-containing t-complex polypeptide-1 (TCP1) antibody exhibited higher expression in patients with SLE than in NCs. To validate the specificity of the anti-TCP1 antibody in SLE, dot blot analysis was conducted using sera from patients with SLE (n = 100), rheumatoid arthritis (RA; n = 25), Behçet’s disease (BD; n = 28), and systemic sclerosis (SSc; n = 30) and NCs (n = 50). The results confirmed the detection of anti-TCP1 antibodies in 79 of 100 patients with SLE, with substantially elevated expression compared to both NCs and patients with other autoimmune diseases. We performed an enzyme-linked immunosorbent assay to determine the relative amounts of anti-TCP1 antibodies; markedly elevated anti-TCP1 antibody levels were detected in the sera of patients with SLE (50.1 ± 17.3 arbitrary unit (AU), n = 251) compared to those in NCs (33.9 ± 9.3 AU), RA (35 ± 8.7 AU), BD (37.5 ± 11.6 AU), and SSc (43 ± 11.9 AU). These data suggest that the anti-TCP1 antibody is a potential diagnostic biomarker for SLE.
- Open Access
- 27 February 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (9) , 5088-5106
LC3B drives transcription-associated homologous recombination via direct interaction with R-loops
Exploring the connection between ubiquitin-like modifiers (ULMs) and the DNA damage response (DDR), we employed several advanced DNA damage and repair assay techniques and identified a crucial role for LC3B. Notably, its RNA recognition motif (RRM) plays a pivotal role in the context of transcription-associated homologous recombination (HR) repair (TA-HRR), a particular subset of HRR pathways. Surprisingly, independent of autophagy flux, LC3B interacts directly with R-loops at DNA lesions within transcriptionally active sites via its RRM, promoting TA-HRR. Using native RNA immunoprecipitation (nRIP) coupled with high-throughput sequencing (nRIP-seq), we discovered that LC3B also directly interacts with the 3′UTR AU-rich elements (AREs) of BRCA1 via its RRM, influencing its stability. This suggests that LC3B regulates TA-HRR both proximal to and distal from DNA lesions. Data from our LC3B depletion experiments showed that LC3B knockdown disrupts end-resection for TA-HRR, redirecting it towards the non-homologous end joining (NHEJ) pathway and leading to chromosomal instability, as evidenced by alterations in sister chromatid exchange (SCE) and interchromosomal fusion (ICF). Thus, our findings unveil autophagy-independent functions of LC3B in DNA damage and repair pathways, highlighting its importance. This could reshape our understanding of TA-HRR and the interaction between autophagy and DDR.
- 27 February 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (9) , 5088-5106
Open AccessLC3B drives transcription-associated homologous recombination via direct interaction with R-loops
Exploring the connection between ubiquitin-like modifiers (ULMs) and the DNA damage response (DDR), we employed several advanced DNA damage and repair assay techniques and identified a crucial role for LC3B. Notably, its RNA recognition motif (RRM) plays a pivotal role in the context of transcription-associated homologous recombination (HR) repair (TA-HRR), a particular subset of HRR pathways. Surprisingly, independent of autophagy flux, LC3B interacts directly with R-loops at DNA lesions within transcriptionally active sites via its RRM, promoting TA-HRR. Using native RNA immunoprecipitation (nRIP) coupled with high-throughput sequencing (nRIP-seq), we discovered that LC3B also directly interacts with the 3′UTR AU-rich elements (AREs) of BRCA1 via its RRM, influencing its stability. This suggests that LC3B regulates TA-HRR both proximal to and distal from DNA lesions. Data from our LC3B depletion experiments showed that LC3B knockdown disrupts end-resection for TA-HRR, redirecting it towards the non-homologous end joining (NHEJ) pathway and leading to chromosomal instability, as evidenced by alterations in sister chromatid exchange (SCE) and interchromosomal fusion (ICF). Thus, our findings unveil autophagy-independent functions of LC3B in DNA damage and repair pathways, highlighting its importance. This could reshape our understanding of TA-HRR and the interaction between autophagy and DDR.
- Open Access
- 16 October 2023
- Published by Wiley in Advanced Science
- Vol. 10 (33) , e2305096
A Cell‐Penetrant Peptide Disrupting the Transcription Factor CP2c Complexes Induces Cancer‐Specific Synthetic Lethality
Despite advances in precision oncology, cancer remains a global public health issue. In this report, proof‐of‐principle evidence is presented that a cell‐penetrable peptide (ACP52C) dissociates transcription factor CP2c complexes and induces apoptosis in most CP2c oncogene‐addicted cancer cells through transcription activity‐independent mechanisms. CP2cs dissociated from complexes directly interact with and degrade YY1, leading to apoptosis via the MDM2‐p53 pathway. The liberated CP2cs also inhibit TDP2, causing intrinsic genome‐wide DNA strand breaks and subsequent catastrophic DNA damage responses. These two mechanisms are independent of cancer driver mutations but are hindered by high MDM2 p60 expression. However, resistance to ACP52C mediated by MDM2 p60 can be sensitized by CASP2 inhibition. Additionally, derivatives of ACP52C conjugated with fatty acid alone or with a CASP2 inhibiting peptide show improved pharmacokinetics and reduced cancer burden, even in ACP52C‐resistant cancers. This study enhances the understanding of ACP52C‐induced cancer‐specific apoptosis induction and supports the use of ACP52C in anticancer drug development.
- 16 October 2023
- Published by Wiley in Advanced Science
- Vol. 10 (33) , e2305096
Open AccessA Cell‐Penetrant Peptide Disrupting the Transcription Factor CP2c Complexes Induces Cancer‐Specific Synthetic Lethality
Despite advances in precision oncology, cancer remains a global public health issue. In this report, proof‐of‐principle evidence is presented that a cell‐penetrable peptide (ACP52C) dissociates transcription factor CP2c complexes and induces apoptosis in most CP2c oncogene‐addicted cancer cells through transcription activity‐independent mechanisms. CP2cs dissociated from complexes directly interact with and degrade YY1, leading to apoptosis via the MDM2‐p53 pathway. The liberated CP2cs also inhibit TDP2, causing intrinsic genome‐wide DNA strand breaks and subsequent catastrophic DNA damage responses. These two mechanisms are independent of cancer driver mutations but are hindered by high MDM2 p60 expression. However, resistance to ACP52C mediated by MDM2 p60 can be sensitized by CASP2 inhibition. Additionally, derivatives of ACP52C conjugated with fatty acid alone or with a CASP2 inhibiting peptide show improved pharmacokinetics and reduced cancer burden, even in ACP52C‐resistant cancers. This study enhances the understanding of ACP52C‐induced cancer‐specific apoptosis induction and supports the use of ACP52C in anticancer drug development.
Anti‐heat shock protein 10 IgG in chronic spontaneous urticaria: Relation with miRNA‐101‐5p and platelet‐activating factor
Background: Anti‐heat shock protein (HSP) autoantibodies are detected in autoimmune diseases. We sought to ascertain whether anti‐HSP10 IgG is present in patients with CSU and to elucidate the role of HSP10 in CSU pathogenesis.Method: Using a human proteome microarray, six potential autoantibodies had higher expression in 10 CSU samples compared with 10 normal controls (NCs). Among them, HSP10 IgG autoantibody was quantified by immune dot‐blot assay in sera from 86 CSU patients and 44 NCs. The serum levels of HSP10 and microRNA‐101‐5p were measured in CSU patients and NCs. The effects of HSP10 and miR‐101‐5p on mast cell degranulation in response to IgE, compound 48/80, and platelet‐activating factor (PAF) were investigated.Results: CSU patients had higher IgG positivity to HSP10 (40.7% vs. 11.4%, p = .001), lower serum HSP10 levels (5.8 ± 3.6 vs. 12.2 ± 6.6 pg/mL, p < .001) than in NCs, and their urticaria severity was associated with anti‐HSP10 IgG positivity, while HSP10 levels were related to urticaria control status. MiR‐101‐5p was increased in CSU patients. PAF enhanced IL4 production in PBMCs from CSU patients. IL‐4 upregulated miR‐101‐5p and reduced HSP10 expression in keratinocytes. Transfection of miR‐101‐5p reduced HSP10 expression in keratinocytes. MiR‐101‐5p promoted PAF‐induced mast cell degranulation, while HSP10 specifically prevented it.Conclusion: A new autoantibody, anti‐HSP10 IgG was detected in CSU patients, which showed a significant correlation with UAS7 scores. A decreased serum HSP10 level was associated with upregulation of miR‐101‐5p due to increased IL‐4 and PAF in CSU patients. Modulation of miR‐101‐5p and HSP10 may be a novel therapeutic approach for CSU.
Anti‐heat shock protein 10 IgG in chronic spontaneous urticaria: Relation with miRNA‐101‐5p and platelet‐activating factor
Background: Anti‐heat shock protein (HSP) autoantibodies are detected in autoimmune diseases. We sought to ascertain whether anti‐HSP10 IgG is present in patients with CSU and to elucidate the role of HSP10 in CSU pathogenesis.Method: Using a human proteome microarray, six potential autoantibodies had higher expression in 10 CSU samples compared with 10 normal controls (NCs). Among them, HSP10 IgG autoantibody was quantified by immune dot‐blot assay in sera from 86 CSU patients and 44 NCs. The serum levels of HSP10 and microRNA‐101‐5p were measured in CSU patients and NCs. The effects of HSP10 and miR‐101‐5p on mast cell degranulation in response to IgE, compound 48/80, and platelet‐activating factor (PAF) were investigated.Results: CSU patients had higher IgG positivity to HSP10 (40.7% vs. 11.4%, p = .001), lower serum HSP10 levels (5.8 ± 3.6 vs. 12.2 ± 6.6 pg/mL, p < .001) than in NCs, and their urticaria severity was associated with anti‐HSP10 IgG positivity, while HSP10 levels were related to urticaria control status. MiR‐101‐5p was increased in CSU patients. PAF enhanced IL4 production in PBMCs from CSU patients. IL‐4 upregulated miR‐101‐5p and reduced HSP10 expression in keratinocytes. Transfection of miR‐101‐5p reduced HSP10 expression in keratinocytes. MiR‐101‐5p promoted PAF‐induced mast cell degranulation, while HSP10 specifically prevented it.Conclusion: A new autoantibody, anti‐HSP10 IgG was detected in CSU patients, which showed a significant correlation with UAS7 scores. A decreased serum HSP10 level was associated with upregulation of miR‐101‐5p due to increased IL‐4 and PAF in CSU patients. Modulation of miR‐101‐5p and HSP10 may be a novel therapeutic approach for CSU.
- Open Access
- 22 April 2023
- Published by Elsevier in Biomaterials
- Vol. 297, 122131
Prussian blue nanozymes coated with Pluronic attenuate inflammatory osteoarthritis by blocking c-Jun N-terminal kinase phosphorylation
- 22 April 2023
- Published by Elsevier in Biomaterials
- Vol. 297, 122131
Open AccessPrussian blue nanozymes coated with Pluronic attenuate inflammatory osteoarthritis by blocking c-Jun N-terminal kinase phosphorylation
- 27 January 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (4) , eadd4969
SUMOylation-mediated PSME3-20 S proteasomal degradation of transcription factor CP2c is crucial for cell cycle progression
Transcription factor CP2c (also known as TFCP2, α-CP2, LSF, and LBP-1c) is involved in diverse ubiquitous and tissue/stage-specific cellular processes and in human malignancies such as cancer. Despite its importance, many fundamental regulatory mechanisms of CP2c are still unclear. Here, we uncover an unprecedented mechanism of CP2c degradation via a previously unidentified SUMO1/PSME3/20 S proteasome pathway and its biological meaning. CP2c is SUMOylated in a SUMO1-dependent way, and SUMOylated CP2c is degraded through the ubiquitin-independent PSME3 (also known as REGγ or PA28)/20 S proteasome system. SUMOylated PSME3 could also interact with CP2c to degrade CP2c via the 20 S proteasomal pathway. Moreover, precisely timed degradation of CP2c via the SUMO1/PSME3/20 S proteasome axis is required for accurate progression of the cell cycle. Therefore, we reveal a unique SUMO1-mediated uncanonical 20 S proteasome degradation mechanism via the SUMO1/PSME3 axis involving mutual SUMO-SIM interaction of CP2c and PSME3, providing previously unidentified mechanistic insights into the roles of dynamic degradation of CP2c in cell cycle progression.
- 27 January 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (4) , eadd4969
SUMOylation-mediated PSME3-20 S proteasomal degradation of transcription factor CP2c is crucial for cell cycle progression
Transcription factor CP2c (also known as TFCP2, α-CP2, LSF, and LBP-1c) is involved in diverse ubiquitous and tissue/stage-specific cellular processes and in human malignancies such as cancer. Despite its importance, many fundamental regulatory mechanisms of CP2c are still unclear. Here, we uncover an unprecedented mechanism of CP2c degradation via a previously unidentified SUMO1/PSME3/20 S proteasome pathway and its biological meaning. CP2c is SUMOylated in a SUMO1-dependent way, and SUMOylated CP2c is degraded through the ubiquitin-independent PSME3 (also known as REGγ or PA28)/20 S proteasome system. SUMOylated PSME3 could also interact with CP2c to degrade CP2c via the 20 S proteasomal pathway. Moreover, precisely timed degradation of CP2c via the SUMO1/PSME3/20 S proteasome axis is required for accurate progression of the cell cycle. Therefore, we reveal a unique SUMO1-mediated uncanonical 20 S proteasome degradation mechanism via the SUMO1/PSME3 axis involving mutual SUMO-SIM interaction of CP2c and PSME3, providing previously unidentified mechanistic insights into the roles of dynamic degradation of CP2c in cell cycle progression.